Corgenix Obtains European Patent for Aspirin Resistance Testing
February 27, 2008 - Corgenix Medical Corp. received notification of European Patent Office (EPO) approval for technology to which Corgenix holds exclusive worldwide licensing rights.
McMaster University (McMaster) of Hamilton, Ontario, is the owner of the patent covering the aspirin resistance measurement method. Corgenix has licensed this technology from McMaster and is presently developing products to capitalize on the European protected technology. The patented technology is also related to Corgenixï¿½ AspirinWorks test kit, which received FDA clearance in 2007.
The EPO patent approval covers the ability to assess a patientï¿½s resistance to the anti-clotting effects of aspirin and also to assess the risk of a cardiovascular event (heart attack or stroke) in patients taking aspirin.
The AspirinWorks test is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which reportedly aids in the qualitative detection of aspirin effect.
For more information: www.corgenix.com
More like this
- Corgenix Signs Deal to Automate Platelet Test Kit Processing
- Corgenix Offers AspirinWorks to Test Platelets for Heart Disease, Stroke Patients
- Atherotech Diagnostics Lab Adds Corgenix AspirinWorks Test for Aspirin Effect
- Corgenix AspirinWorks Test Now Offered Through Quest Diagnostics
- Corgenix AspirinWorks Test Kit Cleared by FDA